✦ LIBER ✦

Methodological considerations in studying natural history of HBeAg-negative and -positive chronic hepatitis B

✍ Scribed by Guohong Cai; Wen Yin

Book ID: 115293878
Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 86 KB
Volume: 32
Category: Article
ISSN: 0106-9543
DOI: 10.1111/j.1478-3231.2011.02688.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Methodological considerations in studyin

Methodological considerations in studying natural history of HBeAg-negative and -positive chronic hepatitis B: authors' reply

✍ Catherine M. N. Croagh; Sally J. Bell; Paul V. Desmond 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 93 KB

Natural history of hbeag-negative chroni

Natural history of hbeag-negative chronic Hepatitis b

✍ Marc G. Ghany; T. Jake Liang 📂 Article 📅 2006 🏛 Current Science Inc. 🌐 English ⚖ 229 KB

New perspectives in the treatment of HBe

New perspectives in the treatment of HBeAg-positive and HBeAg-negative chronic hepatitis B

✍ Thomas Berg 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 141 KB 👁 2 views

BACKGROUND: Available treatments for hepatitis B e antigen (HBeAg)-negative chronic hepatitis B are associated with poor sustained responses. As a result, nucleoside and nucleotide analogues are typically continued indefinitely, a strategy associated with the risk of resistance and unknown long-term

Natural history of extended lamivudine (

Natural history of extended lamivudine (LAM) treatment in patients with HBeAg negative chronic hepatitis B (CHB)

✍ Nicholas Tassopoulos; George Anagnostopoulos; Vana Sypsa; Johanna Delladetsima; 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 112 KB

[514] PREDICTION OF LIVER HISTOPATHOLOGY

[514] PREDICTION OF LIVER HISTOPATHOLOGY BY NON-INVASIVE MODELS IN HBeAg-POSITIVE AND HBeAg-NEGATIVE CHRONIC HEPATITIS B

✍ S. Roberts; G.K. Lau; T. Piratvisuth; K. Luo; P. Marcellin; F. Bonino; P. Farci; 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 155 KB

Efficacy of lamivudine in HBeAg-negative

Efficacy of lamivudine in HBeAg-negative chronic hepatitis B

✍ Mario Rizzetto 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 136 KB

## Abstract Hepatitis B e antigen (HBeAg)‐negative chronic hepatitis B results from infection with hepatitis B virus mutants unable to produce HBeAg. It accounts for 7–30% of patients with chronic hepatitis B virus (HBV) worldwide, with the highest rates reported for Mediterranean Europe and Asia.